Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Core Scientific, Inc. Tranche 2 Warrants (CORZZ) provides access to regulatory documents that explain how these warrants relate to Core Scientific’s common stock and broader capital structure. Core Scientific’s filings under the Exchange Act identify CORZZ as a class of warrants listed on the Nasdaq Global Select Market, each whole warrant exercisable for one share of Core Scientific common stock at a specified exercise price.
Through Forms 8-K and other filings, Core Scientific discloses material events affecting CORZZ, such as the satisfaction of trading price conditions that make tranche 2 warrants exercisable for a defined period. These filings describe the warrant terms, including exercise prices and the number of warrants outstanding, and may reference related press releases furnished as exhibits. Investors can review these documents to understand when and how CORZZ can be exercised and how many shares of common stock each warrant represents.
Filings also place CORZZ in the context of Core Scientific’s capital structure and corporate transactions. In connection with the company’s emergence from Chapter 11 reorganization, SEC disclosures outline the issuance of new common stock, tranche 1 warrants, tranche 2 warrants and other securities. Later 8-K filings describe an Agreement and Plan of Merger under which CoreWeave, Inc. is expected to acquire Core Scientific in an all-stock transaction. These documents explain how each share of Core Scientific common stock would convert into CoreWeave Class A common stock and how existing warrants, including tranche 2 warrants, would be adjusted into new warrants exercisable for CoreWeave shares based on an exchange ratio.
On Stock Titan, users can review real-time updates from EDGAR alongside AI-powered summaries that highlight key points from Core Scientific’s 8-Ks and other filings. These summaries help clarify the implications of warrant-related disclosures, merger terms, and other regulatory information without requiring readers to parse every technical detail. The filings page also surfaces information on registered securities, including CORZ, CORZW and CORZZ, so investors can see how the different instruments interact within Core Scientific’s disclosed capital structure.
Core Scientific, Inc. Chief Executive Officer Adam Taylor reported equity compensation activity involving performance-based restricted stock units (PSUs) and related tax withholding. On March 31, 2026, he acquired 741,545 shares of Common Stock at $0.00 per share upon vesting and settlement of previously granted PSUs tied to specified performance criteria.
On the same date, 315,307 shares of Common Stock were withheld at $14.96 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, a non–open-market, tax-related disposition. After these transactions, Taylor directly held 4,557,388 shares of Common Stock, reflecting routine compensation and tax-settlement mechanics rather than open-market buying or selling.
Core Scientific, Inc. officer Todd M. Duchene reported a mix of equity compensation and share dispositions. On March 31, he received 216,734 shares of common stock through the settlement of performance-based restricted stock units, while 97,652 shares were withheld to cover tax obligations upon vesting.
On April 1, Duchene sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $15.2523 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 2,047,089 shares of Core Scientific common stock.
CORZ filing a Form 144 notice for the proposed sale of 140,000 shares of Common Stock, reported on 04/01/2026. The filing lists two underlying lots—59,388 shares from a merger/acquisition and 80,612 shares from Restricted Stock Units—that together equal the 140,000 shares.
The filing shows an aggregate amount of $2,094,400.00 and a reported shares outstanding figure of 315,332,655 as of 04/01/2026. The broker-dealer listed is Morgan Stanley Smith Barney LLC (Nasdaq). The notice documents an intended sale by an issuer-related source.
Core Scientific, Inc. outlines its 2025 shift toward high‑density colocation and AI/HPC infrastructure and seeks stockholder votes at its May 12, 2026 virtual annual meeting. The company expanded its CoreWeave agreement by 70 MW to about 590 MW of contracted capacity across five sites, with projected revenue of more than $10 billion over 12 years.
Across four locations, it advanced over 1 million square feet of data center shell, installed nearly $2 billion of infrastructure and supported more than 5 million labor hours, part of more than $5 billion of infrastructure investment largely expected to be funded by the customer. About 350 MW had been energized, with over 180 MW online and billing.
The proxy statement details three proposals: electing five directors, an advisory say‑on‑pay vote on named executive officer compensation, and ratification of KPMG as auditor. It also describes board independence, committee structure, a new cooperation agreement with Two Seas Capital on adding independent directors, and a revised executive pay program that increases performance‑based equity and links PSU vesting partly to relative total shareholder return.
Core Scientific EVP and CFO James P. Nygaard Jr. reported a tax-withholding disposition of Common Stock. On the stated date, 98,671 shares were withheld at $16.42 per share to satisfy withholding tax obligations upon the vesting of restricted stock units. Following this event, Nygaard directly holds 922,982 shares of Core Scientific Common Stock. This was a mechanical tax payment using shares rather than an open-market sale.
Core Scientific Inc — The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares beneficially owned of Common Stock as of 03/13/2026. The filing explains an internal realignment on January 12, 2026 that disaggregated certain Vanguard subsidiaries' holdings from The Vanguard Group, Inc.
The reporting person certifies sole and shared voting and dispositive powers of 0 and states ownership is below 5%. The amendment is signed by Ashley Grim on 03/26/2026.
Core Scientific, Inc. expanded its short-term credit facility by an additional $500.0 million under an accordion feature, bringing total term loan commitments to $1.0 billion. The company borrowed the full incremental amount at a rate of SOFR plus 250 basis points.
Proceeds from this 364-day facility are expected to be used for general corporate purposes tied to developing data center assets, including equipment purchases, pre-development work, real estate acquisitions and energy procurement for high-density colocation and AI-focused infrastructure.
Two Seas Capital and affiliates filed an amended Schedule 13D reporting beneficial ownership of 17,466,679 shares of Core Scientific, Inc. common stock, equal to about 5.5% of the outstanding shares. This total includes 313,646 shares issuable upon exercise of warrants and options to purchase 2,534,000 shares.
The filing explains that Core Scientific had 315,332,655 shares outstanding as of February 26, 2026, plus the 313,646 warrant shares. Two Seas Capital, its general partner and Sina Toussi share voting and investment power over securities held for various funds and accounts under investment management agreements.
The amendment also updates a Cooperation Agreement: on March 15, 2026, Two Seas Capital agreed to waive a requirement that Core Scientific appoint one independent director by that date, provided the company remains in compliance with the agreement and makes the appointment by May 30, 2026.
Core Scientific EVP and CFO James P. Nygaard Jr. reported a tax-related share disposition. On March 17, 2026, 92,725 shares of Common Stock were withheld at $16.42 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, rather than sold in the open market.
After this withholding, Nygaard directly owns 928,928 shares of Core Scientific common stock. Footnotes indicate that a portion of his holdings also reflects earlier in-kind share distributions received for no cash consideration.
Valiant Capital Management reports passive stake in Core Scientific. Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen jointly filed a Schedule 13G reporting beneficial ownership of 16,212,903 shares of Core Scientific, Inc. Common Stock, representing 5.1% of the class based on February 26, 2026.
The filing states the reporting persons have shared voting and shared dispositive power over the 16,212,903 shares. The Funds hold the shares for the benefit of their investors and no single Fund holds more than 5% of outstanding Common Stock.